Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
BALA CYNWYD, Pa. Feb.14, 2024 - Larimar Therapeutics, Inc.(Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, has recently disclosed the pricing of its underwritten public offering of 17,162,472 shares of its common stock.The shares are priced at $8.74 per share, which reflects the closing price of its common stock on February 13, 2024.This offering is expected to generate approximately $150.0 million in gross proceeds for the company, before deducting underwriting discounts, commissions, and other offering expenses.
Larimar Therapeutics has also granted the underwriters a 30-day option to purchase an additional 2,574,370 shares of its common stock at the public offering price, less underwriting discounts and commissions.It’s worth noting that all shares of common stock being offered are issued by Larimar Therapeutics.The company plans to close the offering on or around February 16, 2024, contingent upon the fulfillment of customary closing conditions.
These recent developments are significant for Larimar Therapeutics as it aims to raise capital to further its endeavors in developing treatments for complex rare diseases.Larimar is dedicated to addressing the unmet medical needs of patients suffering from these conditions and has made significant progress in its clinical trials.
The timing of this public offering aligns with Larimar Therapeutics’ ongoing commitment to expanding its research and development efforts.With the funds generated from this offering, the company will be better equipped to advance its pipeline of promising therapies and potentially accelerate the development of novel treatments.
As a clinical-stage biotechnology company, Larimar Therapeutics has placed a strong emphasis on tackling rare diseases, which affect a small subset of the population.While these diseases may individually impact only a limited number of individuals, the collective burden is substantial.By developing innovative treatments, Larimar aims to improve the lives of patients and their families, bringing hope to those previously left without viable options.
It is noteworthy to mention that Larimar Therapeutics currently has 43.903738 million shares outstanding, with a market price of $8.74 per share.The pricing of the underwritten public offering is aligned with the current market value, indicating confidence in the company’s potential and the support it has garnered from investors.
In conclusion, Larimar Therapeutics’ announcement regarding the pricing of its underwritten public offering of common stock signifies a significant milestone for the company.With the substantial proceeds expected from this offering, Larimar will be well-positioned to advance its research and development efforts, ultimately bringing new hope to patients suffering from complex rare diseases.
Comments